CA2972822C - Anticorps fcrn et leurs procedes d'utilisation - Google Patents

Anticorps fcrn et leurs procedes d'utilisation

Info

Publication number
CA2972822C
CA2972822C CA2972822A CA2972822A CA2972822C CA 2972822 C CA2972822 C CA 2972822C CA 2972822 A CA2972822 A CA 2972822A CA 2972822 A CA2972822 A CA 2972822A CA 2972822 C CA2972822 C CA 2972822C
Authority
CA
Canada
Prior art keywords
seq
sequence
cdr
antibody
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2972822A
Other languages
English (en)
Other versions
CA2972822A1 (fr
Inventor
Marilyn Kehry
David J. King
Leona E. Ling
Iii Meador James
Sucharita Roy
Anthony Manning
Original Assignee
Momenta Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Momenta Pharmaceuticals Inc filed Critical Momenta Pharmaceuticals Inc
Priority claimed from PCT/US2016/015720 external-priority patent/WO2016123521A2/fr
Publication of CA2972822A1 publication Critical patent/CA2972822A1/fr
Application granted granted Critical
Publication of CA2972822C publication Critical patent/CA2972822C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

La présente invention concerne des anticorps qui ont une grande affinité de liaison au récepteur Fc néonatal humain (FcRn). Ces anticorps anti-FcRn sont utiles, par exemple, pour favoriser la clairance des auto-anticorps chez un sujet, pour supprimer la présentation de l'antigène chez un sujet, pour bloquer une réponse immunitaire, par exemple pour bloquer une activation basée sur des complexes immuns de la réponse immunitaire chez un sujet, et pour traiter des maladies immunologiques (par exemple, des maladies auto-immunes) chez un sujet.
CA2972822A 2015-01-30 2016-01-29 Anticorps fcrn et leurs procedes d'utilisation Active CA2972822C (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562110071P 2015-01-30 2015-01-30
US62/110,071 2015-01-30
US201562258082P 2015-11-20 2015-11-20
US62/258,082 2015-11-20
PCT/US2016/015720 WO2016123521A2 (fr) 2015-01-30 2016-01-29 Anticorps fcrn et leurs procédés d'utilisation

Publications (2)

Publication Number Publication Date
CA2972822A1 CA2972822A1 (fr) 2016-08-04
CA2972822C true CA2972822C (fr) 2025-08-12

Family

ID=

Similar Documents

Publication Publication Date Title
AU2022201145B2 (en) FcRn antibodies and methods of use thereof
US20230049725A1 (en) FcRn Antibodies and Methods of Use Thereof
CA2972822C (fr) Anticorps fcrn et leurs procedes d'utilisation
HK40103769A (en) Fcrn antibodies and methods of use thereof
HK1247218B (en) Fcrn antibodies and methods of use thereof
HK1247218A1 (en) Fcrn antibodies and methods of use thereof
BR122021007991B1 (pt) Uso de anticorpos que se ligam a fcrn humana
BR112017015287B1 (pt) Anticorpos isolados que se ligam a fcrn humano, e composição farmacêutica